Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone
PR Newswire - Mon Dec 22, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the first cohort of subjects has been dosed in a pharmacokinetic and pharmacodynamic study with d-Methadone, the company's N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain.
Diabetic Neuropathic Pain - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/qm4xdv/diabetic) has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - AstraZeneca - Eli Lilly and Company - BioDelivery Sciences - Daiichi Sankyo - Acorda Therapeutics - Astellas Pharma - Glenmark Pharmaceuticals - KunWha Pharmaceutical - Mertiva - Grunenthal - Kyorin Pharmaceutical - Bial - Lohocla Research - Relmada Therapeutics - Sphaera Pharma - Immune Pharmaceuticals - AbbVie - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/qm4xdv/diabetic
IMNP: 1.89 (+0.02), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Relmada Therapeutics Announces Results of Annual Shareholders Meeting
PR Newswire - Thu Dec 18, 3:35PM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced the results of its annual general meeting of shareholders held today.
Postherpetic Neuralgia - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/489mg3/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Allergan - Acorda Therapeutics - Daewoong Pharmaceutical - Pfizer - Purdue Pharma - Teva Pharmaceutical Industries - Nuvo Research Inc. - Arcion Therapeutics, Inc. - NeurAxon, Inc. - Winston Pharmaceuticals, Inc. - Bial - Portela & Ca, S.A. - Spinifex Pharmaceuticals Pty Limited - Relmada Therapeutics, Inc. - Aestus Therapeutics, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Immune Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/48...stherpetic
AGN: 210.12 (+0.95), TEVA: 57.09 (+0.33), IMNP: 1.89 (+0.02), BMY: 59.15 (-0.01), ACOR: 39.14 (+0.74)
Relmada Therapeutics hires Christine Silverstein as director of Investor Relations
M2 - Thu Dec 11, 6:17AM CST
Pharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) revealed on Wednesday the election of Christine Silverstein as director of its investor relations.
Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations
PR Newswire - Wed Dec 10, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Christine Silverstein as director of investor relations, effective immediately. She will report to Michael Becker, senior vice president of finance and corporate development at Relmada.
Relmada Therapeutics to begin first pharmacokinetic and pharmacodynamic study of d-Methadone for neuropathic pain in Canada
M2 - Wed Dec 03, 7:09AM CST
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) reported on Tuesday the receipt of Health Canada's No Objection Letter (NOL) to start the first pharmacokinetic and pharmacodynamic study of its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain, d-Methadone.
Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference
PR Newswire - Wed Dec 03, 7:00AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, is pleased to participate in the Buzz of BIO Contest in connection with the 2015 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference features leading private and emerging public companies and will take place February 9-10, 2015 at the Waldorf Astoria in New York, NY.
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
PR Newswire - Tue Dec 02, 7:30AM CST
Novel Product Virtually Devoid of Opioid Activity Being Studied in Neuropathic Pain.
Relmada Therapeutics To Present At LD MICRO Conference
PR Newswire - Mon Nov 24, 7:30AM CST
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.
Relmada Therapeutics hires Michael Becker as SVP of finance and corporate development to broaden and strengthen its senior leadership team
M2 - Wed Nov 05, 6:31AM CST
Biopharmaceutical company Relmada Therapeutics (OtherOTC:RLMD) disclosed on Tuesday the election of Michael D. Becker as senior vice president of its finance and corporate development with immediate effect.
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
PR Newswire - Tue Nov 04, 7:00AM CST
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Marketwired - Wed Oct 29, 8:08AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with four novel pain treatment drugs currently under development in its pipeline, received a healthy injection of more than $15 million in capital last week that will assist the company in the advancement of its work to bring those products to the largest drug prescription market in the world - the treatment of pain.
Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
PR Newswire - Thu Oct 16, 7:00AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants were exercised at $1.50 per share, resulting in gross proceeds of approximately $15.2M for the Company.
New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.
Marketwired - Thu Oct 09, 8:16AM CDT
After careful analysis, Stock Market Media Group (SMMG), a research and content development IR firm, announces that it has initiated coverage on Relmada Therapeutics, Inc. (OTCQB: RLMD), a biopharmaceutical firm with 4 novel drugs currently in its pipeline under development. In a new Report, SMMG examines the company's unique drug development strategy, its pipeline of drugs for the treatment of pain, the multi-billion dollar market in which the biotech's products will compete, and both the impressive management team and Scientific Advisory Board that will lead the firm into the future.
Relmada Therapeutics names Julie J. Chen as director of Finance and Operations to strengthen financial and business operations
M2 - Fri Oct 03, 4:35AM CDT
Pharmaceutical company Relmada Therapeutics (OTC BB :RLMD) reported on Thursday the addition of Julie J. Chen as director of its Finance and Operations.
Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations
PR Newswire - Thu Oct 02, 7:15AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Julie J. Chen as its Director of Finance and Operations.
Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
PR Newswire - Thu Sep 18, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of Senior Director of Clinical Development.
Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
PR Newswire - Tue Sep 16, 6:45AM CDT
Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER, a new tamper-resistant, extended release form of levorphanol. Gavril Pasternak, MD, PhD, of MSKCC is the lead investigator for these studies.